Argenx Se (ARGX) Revenue (2016 - 2026)
Argenx Se's (ARGX) quarterly Revenue came in at $1.6 billion in Q2 2026, up 64.03% YoY from $948.6 million in Q2 2025, and up 19.88% on a QoQ basis from $1.3 billion in Q1 2026.
Argenx Se (ARGX) Revenue (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of Revenue data on file, last reported at $1.6 billion in Q2 2026.
- Quarterly Revenue rose 64.03% year-over-year to $1.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.3 billion (up 72.76% YoY) and the FY2025 annual result came in at $4.2 billion, up 88.63% from the prior year.
- Revenue grew to $1.6 billion in Q2 2026, from $1.3 billion in the prior quarter.
- In the past five years, Revenue ranged from a high of $1.6 billion in Q2 2026 to a low of $21.2 million in Q1 2022.
- A 5-year average of $599.0 million and a median of $438.0 million in 2024 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue sank 99.98% — and 2023, when it surged 930.2%.
- Tracing ARGX's Revenue over 5 years: stood at $173.4 million in 2022, then soared by 115.89% to $374.4 million in 2023, then surged by 96.87% to $737.0 million in 2024, then soared by 74.46% to $1.3 billion in 2025, then grew by 21.02% to $1.6 billion in 2026.
- The last three Revenue figures came in at $1.6 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.56 Bn |
| Mar 31, 2026 | 1.30 Bn |
| Dec 31, 2025 | 1.29 Bn |
| Sep 30, 2025 | 1.13 Bn |
| Jun 30, 2025 | 948.59 Mn |
| Mar 31, 2025 | 790.00 Mn |
| Dec 31, 2024 | 736.97 Mn |
| Sep 30, 2024 | 573.00 Mn |
| Jun 30, 2024 | 477.64 Mn |
| Mar 31, 2024 | 398.28 Mn |
| Dec 31, 2023 | 374.35 Mn |
| Sep 30, 2023 | 329.10 Mn |
| Jun 30, 2023 | 269.31 Mn |
| Mar 31, 2023 | 218.02 Mn |
| Dec 31, 2022 | 173.40 Mn |
| Sep 30, 2022 | 131.33 Mn |
| Jun 30, 2022 | 74.83 Mn |
| Mar 31, 2022 | 21.16 Mn |
| Dec 31, 2021 | 26.02 Mn |
| Sep 30, 2021 | 857.00 Bn |